Envoya
Envoya is dedicated to revolutionizing healthcare by providing safer and more effective delivery systems for genetic material, enabling groundbreaking treatments for various diseases. They focus on advanced biomedical technologies, polymer-based nanoparticles for targeted delivery, and leverage AI-driven design to optimize nanoparticle compositions for gene therapy. Their mission emphasizes innovation, patient-centricity, integrity, and continuous learning to accelerate the development of life-changing gene therapies.
Industries
Nr. of Employees
small (1-50)
Products
Polymer-based nanoparticle delivery system (pre-made and custom)
Polymeric nanoparticle formulations intended to encapsulate and deliver nucleic acid payloads (siRNA, mRNA, plasmid DNA, CRISPR) with reported in vitro and murine in vivo performance.
Proof-of-concept and positive-control kits (reporter, CRISPR, siRNA)
Pre-made control kits for laboratory assays including fluorescent reporter kits for mRNA/DNA, CRISPR genome-editing kits, and siRNA knockdown kits validated for use in human and murine cell lines.
Polymer-based nanoparticle delivery system (pre-made and custom)
Polymeric nanoparticle formulations intended to encapsulate and deliver nucleic acid payloads (siRNA, mRNA, plasmid DNA, CRISPR) with reported in vitro and murine in vivo performance.
Proof-of-concept and positive-control kits (reporter, CRISPR, siRNA)
Pre-made control kits for laboratory assays including fluorescent reporter kits for mRNA/DNA, CRISPR genome-editing kits, and siRNA knockdown kits validated for use in human and murine cell lines.
Services
On-demand formulation and encapsulation of user-provided genetic payloads into polymeric nanoparticles, including optimization of loading and transfection performance.
Machine-learning-driven generation of de novo peptide ligands intended to target nanoparticles to specified cells or tissues based on receptor binding data.
Strategic partnerships to co-develop nanoparticle-peptide solutions aligned with partner therapeutic goals, including customization and scale-up planning.
On-demand formulation and encapsulation of user-provided genetic payloads into polymeric nanoparticles, including optimization of loading and transfection performance.
Machine-learning-driven generation of de novo peptide ligands intended to target nanoparticles to specified cells or tissues based on receptor binding data.
Strategic partnerships to co-develop nanoparticle-peptide solutions aligned with partner therapeutic goals, including customization and scale-up planning.
Expertise Areas
- Gene delivery and nanoparticle therapeutics
- Polymer chemistry for drug delivery
- AI/ML-driven design for targeting and formulation
- Peptide ligand design for receptor targeting
Key Technologies
- Polymer-based nanoparticles
- AI/ML for peptide design
- AI/ML for polymer composition selection
- Peptide-mediated targeting
News & Updates
A recent publication by Envoya details the in vitro characterization of their polymeric nanoparticles encapsulating plasmid DNA, advancing gene therapy research.
Envoya shared their poster from the Cell & Gene Therapy Summit 2024, highlighting their latest advancements in gene delivery technology.
Patents
Eran Orr, Co-founder & Chairman of the Board, has a portfolio of 5 approved patents.
A recent publication by Envoya details the in vitro characterization of their polymeric nanoparticles encapsulating plasmid DNA, advancing gene therapy research.
Envoya shared their poster from the Cell & Gene Therapy Summit 2024, highlighting their latest advancements in gene delivery technology.
Patents
Eran Orr, Co-founder & Chairman of the Board, has a portfolio of 5 approved patents.